Ripple Therapeutic’s Tom Reeves to Present at BIO CEO & Investor Conference

TORONTO, ON, CANADA / FEBRUARY 11, 2022 - Ripple Therapeutics announced today that Tom Reeves, President & CEO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Hosted annually by the Biotechnology Innovation Organization (BIO) for over 20 years, the conference is focused on emerging public and private companies, offering a meeting place for institutional investors, industry analysts, and senior biotech executives. The conference draws biotech companies looking to make the connections needed to take their products to the next phase.

Ripple is currently enrolling patients in RIPPLE-1, a Phase II clinical trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting DME (diabetic macular edema) and RVO (retinal vein occlusion) patients.  The trial seeks to provide a much-needed treatment option: a safer steroid implant with an extended clinical benefit.

Ripple is developing a full product pipeline including sustained release therapeutics for glaucoma, post cataract surgery and AMD.  Ripple’s glaucoma product (RTC-1119) is an intracameral prostaglandin implant for primary open-angle glaucoma.  The target product profile for RTC-1119 is to provide controlled, predictable drug release for 6-12 months and to allow retreatments as required.  The product is currently in preclinical development and the company is on target to submit a pre-IND in the second quarter of 2022.

About Ripple Therapeutics

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery.  The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients.  Ripple has a full product pipeline in development.

About BIO
BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Subscribe to Good Day BIO.

Media Contact

Julie Fotheringham, V.P. Marketing, People & Culture

M: 416-951-7988 E: